Home Other Building Blocks 1229194-11-9
1229194-11-9,MFCD16038915
Catalog No.:AA000JOQ

1229194-11-9 | Edoxaban tosylate hydrate

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98+%
in stock  
$6.00   $4.00
- +
5mg
98+%
in stock  
$7.00   $5.00
- +
10mg
98+%
in stock  
$9.00   $7.00
- +
100mg
98%(HPLC)
in stock  
$43.00   $30.00
- +
250mg
98%(HPLC)
in stock  
$86.00   $60.00
- +
1g
98%
in stock  
$211.00   $148.00
- +
5g
98%
in stock  
$610.00   $427.00
- +
10g
98%
in stock  
$1,009.00   $706.00
- +
25g
98%
in stock  
$2,007.00   $1,405.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA000JOQ
Chemical Name:
Edoxaban tosylate hydrate
CAS Number:
1229194-11-9
Molecular Formula:
C31H40ClN7O8S2
Molecular Weight:
738.2744
MDL Number:
MFCD16038915
SMILES:
OS(=O)(=O)c1ccc(cc1)C.CN1CCc2c(C1)sc(n2)C(=O)N[C@@H]1C[C@H](CC[C@@H]1NC(=O)C(=O)Nc1ccc(cn1)Cl)C(=O)N(C)C.O
Properties
Computed Properties
 
Complexity:
1090  
Covalently-Bonded Unit Count:
3  
Defined Atom Stereocenter Count:
3  
Heavy Atom Count:
49  
Hydrogen Bond Acceptor Count:
12  
Hydrogen Bond Donor Count:
5  
Rotatable Bond Count:
6  

Downstream Synthesis Route

[1]CurrentPatentAssignee:MIRAEFINECHEMICALCOLTD-KR2022/87933,2022,ALocationinpatent:Paragraph0123-0126

[1]CurrentPatentAssignee:MIRAEFINECHEMICALCOLTD-KR2022/87933,2022,A

[1]CurrentPatentAssignee:MIRAEFINECHEMICALCOLTD-KR2022/87933,2022,A

[1]CurrentPatentAssignee:MIRAEFINECHEMICALCOLTD-KR2022/87933,2022,A

Literature

Title: Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Journal: Clinical pharmacokinetics 20160101

Title: Overview of the new oral anticoagulants: opportunities and challenges.

Journal: Arteriosclerosis, thrombosis, and vascular biology 20150501

Title: The role of factor Xa inhibitors in venous thromboembolism treatment.

Journal: Vascular health and risk management 20150101

Title: Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

Journal: Thrombosis and haemostasis 20121101

Title: Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

Journal: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

Title: Oral direct factor Xa inhibitors.

Journal: Circulation research 20120928

Title: Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.

Journal: Thrombosis research 20120901

Title: The promise of novel direct oral anticoagulants.

Journal: Best practice & research. Clinical haematology 20120901

Title: Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

Journal: Thrombosis and haemostasis 20120701

Title: Long-term benefits of preventing venous thromboembolic events.

Journal: Current medical research and opinion 20120601

Title: Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.

Journal: Critical pathways in cardiology 20120601

Title: In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

Journal: Thrombosis research 20120401

Title: Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.

Journal: Circulation journal : official journal of the Japanese Circulation Society 20120101

Title: Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.

Journal: Thrombosis and haemostasis 20111201

Title: Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.

Journal: Thrombosis and haemostasis 20111201

Title: [Current status and future of anti-Xa inhibitors].

Journal: Rinsho shinkeigaku = Clinical neurology 20111101

Title: The new oral anticoagulants.

Journal: Clinical medicine (London, England) 20111001

Title: Edoxaban for the prevention of thromboembolic events after surgery.

Journal: Drugs of today (Barcelona, Spain : 1998) 20111001

Title: [Thromboembolic prophylaxis 2011: is warfarin on the wane?].

Journal: Giornale italiano di cardiologia (2006) 20110901

Title: Edoxaban: a new oral direct factor xa inhibitor.

Journal: Drugs 20110820

Title: Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.

Journal: Future cardiology 20110701

Title: [New anticoagulants in the prevention and treatment of venous thromboembolism].

Journal: Orvosi hetilap 20110619

Title: Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

Journal: Thrombosis and haemostasis 20110601

Title: Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.

Journal: Thrombosis and haemostasis 20110301

Title: Factor Xa and thrombin as targets for new oral anticoagulants.

Journal: Thrombosis research 20110101

Title: Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

Journal: Annual review of medicine 20110101

Title: Edoxaban tosylate.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

Title: A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.

Journal: Journal of thrombosis and haemostasis : JTH 20101101

Title: Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

Journal: Thrombosis research 20101001

Title: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Journal: American heart journal 20101001

Title: Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

Journal: Thrombosis and haemostasis 20100901

Title: Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

Journal: Thrombosis and haemostasis 20100901

Title: [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801

Title: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Journal: Journal of clinical pharmacology 20100701

Title: Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.

Journal: Current opinion in cardiology 20100701

Title: New anticoagulants for atrial fibrillation.

Journal: Seminars in thrombosis and hemostasis 20090701

Title: DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

Journal: Journal of thrombosis and haemostasis : JTH 20080901

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:1229194-11-9 Molecular Formula|1229194-11-9 MDL|1229194-11-9 SMILES|1229194-11-9 Edoxaban tosylate hydrate